Osmind is a public benefit corporation dedicated to advancing mental health treatment and research. Founded in 2020 by Lucia Huang and Jimmy Qian, the San Francisco-based company develops a specialized technology platform, including an Electronic Health Record (EHR) system, tailored for mental health clinicians and researchers. This platform is designed to support innovative treatments, particularly for treatment-resistant mental health conditions, such as psychedelic-assisted therapies, ketamine treatments, and neuromodulation techniques like transcranial magnetic stimulation (TMS).
The company's mission is to empower clinicians with tools that streamline workflows, enhance patient care, and facilitate the collection of real-world data. Osmind's EHR system is specifically built for interventional psychiatric treatment workflows, incorporating features like mood monitoring, validated questionnaires with automated follow-ups, and tools to assist with insurance reimbursement. By aggregating anonymized data, Osmind aims to generate valuable insights that can inform best practices, accelerate the development of new therapies, and contribute to precision psychiatry. This focus on data-driven care allows healthcare professionals to better understand treatment efficacy and personalize care for individuals. Osmind collaborates with academic institutions, life sciences companies, and organizations like the American Psychiatric Association to further its research goals and improve patient access to cutting-edge mental health care. The platform supports a large network of interventional psychiatry practices across the United States, fostering a community committed to measurement-informed care and advancing the science of mental health.